GlassScriptPhysician profile
Arnold C Toback
NPI 1194749291
$10,466.79
in general payments reported to CMS, 2019-2025
36 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $848 · 2021: $1,529 · 2022: $1,392 · 2023: $1,938 · 2024: $1,506 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,553 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,553.37 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,329.90 | 2020-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $1,153.86 | 2019-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $1,027.85 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $764.10 | 2019-2025 | |
| Pfizer INC. | $698.65 | 2019-2025 | |
| Genzyme Corporation | $639.26 | 2019-2025 | |
| Janssen Biotech, INC. | $631.81 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $626.53 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $602.89 | 2019-2023 | Jublia |
| Leo Pharma INC. | $544.89 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $425.52 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $364.06 | 2019-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $230.69 | 2019-2025 | |
| Ucb, INC. | $197.09 | 2022-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $149.05 | 2019-2023 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $103.21 | 2019-2022 | |
| Botanix Sb INC | $102.39 | 2025 | Sofdra |
| Almirall LLC | $97.48 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $85.26 | 2023-2024 | Ycanth |
| Celgene Corporation | $80.55 | 2019 | |
| Biofrontera INC. | $76.89 | 2019-2024 | Ameluz, Rhodoled Xl, Xepi |
| Arcutis Biotherapeutics, INC. | $64.46 | 2023-2025 | Zoryve |
| Encore Dermatology INC. | $63.44 | 2019 | |
| Journey Medical Corporation | $61.83 | 2022 | |
| Organon LLC | $51.79 | 2025 | Vtama |
| Dermira, INC. | $42.16 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $39.74 | 2025 | Natroba, Spinosad |
| Mission Pharmacal Company | $34.46 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $30.37 | 2020 | |
| Sebela Pharmaceuticals INC. | $25.65 | 2023 | Pramosone, Naftin |
| Dermavant Sciences, INC. | $22.74 | 2023 | Vtama |
| Dusa Pharmaceuticals, INC. | $21.88 | 2019 | |
| Merz North America, INC. | $21.83 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $19.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.31 | 2024 | Sotyktu |
| Allergan, INC. | $15.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Toback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.